Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like L*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator gross_sales_us_dollars gross_sales_us_dollars_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000521 La Jolla Pharmaceutical Company 04/29/2025 68547050102 Giapreza 2.5 mg/mL SDV Injection, Intravenous 01/02/2025 145.00 1765.00 01/06/2037 Single Source Drug None None None 1 Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices.  Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price. None A change or improvement in the product does not necessitate the price increase. None None None None None None None None None None None None
Rx0000089 Lannett Company, Inc. 04/25/2025 54838050280 HydrOXYzine HCl, 10 mg/5 mL Solution, 473 mL bottle 01/21/2025 19.26 115.56 None Non-innovator Multiple Source Drug None None None 1 The change in WAC price reflects the increased cost to supply efficiently to patients due to recent API increase for this molecule incremental supply chain and manufacturing expense and marketing costs. None No change or improvement. None None None None None None None None None None None None
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994001116 DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS 01/01/2025 348.76 5714.35 05/04/2037 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994001104 DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS 01/01/2025 90.51 1483.01 05/04/2037 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009136 LEU TechneLite® (Technetium Tc99m Generator) 1000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 237.04 4187.72 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009109 LEU TechneLite® (Technetium Tc99m Generator) 10000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 805.64 14232.95 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009110 LEU TechneLite® (Technetium Tc99m Generator) 12500 Ci 50 MIL/ML INJ 1 vial 01/01/2025 947.22 16734.19 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009111 LEU TechneLite® (Technetium Tc99m Generator) 15000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 1165.08 20583.07 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009112 LEU TechneLite® (Technetium Tc99m Generator) 18000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 1433.04 25317.12 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009173 LEU TechneLite® (Technetium Tc99m Generator) 2000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 299.08 5283.81 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009192 LEU TechneLite® (Technetium Tc99m Generator) 2500 Ci 50 MIL/ML INJ 1 vial 01/01/2025 328.79 5808.70 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009101 LEU TechneLite® (Technetium Tc99m Generator) 3000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 368.33 6507.20 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009103 LEU TechneLite® (Technetium Tc99m Generator) 4000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 430.32 7602.35 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009104 LEU TechneLite® (Technetium Tc99m Generator) 4500 Ci 50 MIL/ML INJ 1 vial 01/01/2025 464.67 8209.16 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009105 LEU TechneLite® (Technetium Tc99m Generator) 5000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 500.32 8839.05 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009106 LEU TechneLite® (Technetium Tc99m Generator) 6000 Ci 50 MIL/ML INJ 1 vial 01/01/2025 565.11 9983.60 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994009107 LEU TechneLite® (Technetium Tc99m Generator) 7500 Ci 50 MIL/ML INJ 1 vial 01/01/2025 662.05 11696.22 07/01/2029 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009 Lantheus Medical Imaging, Inc. 04/08/2025 11994000602 NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) 01/01/2025 213.57 7332.65 11/23/2008 Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000413 Leadiant Biosciences, Inc. 04/03/2025 54482002002 Cystaran Ophthalmic Solution 0.44 %, 15ML, Unit-of-Use, Single Bottle 01/01/2025 424.64 2597.00 None Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000413 Leadiant Biosciences, Inc. 04/03/2025 54482005401 Matulane Oral Capsule 50 MG, 100 Each, Single Bottle 01/01/2025 1925.36 14852.00 None Single Source Drug None None None 1 None 1 None 1 None None None None None None None None None None None
Rx0000276 LEO Pharma Inc. 04/18/2025 50222034604 Adbry (tralokinumab-ldrm) solution injection, 150 mg/mL, 2 cartons in 1 multipack > 2 syringes in 1 carton > 1 mL in 1 syringe 01/01/2025 230.34 4069.37 01/09/2027 Single Source Drug None None None 1 LEO increased the price due to increasing competition and a growing utilization of our product in once monthly dosing. This is additionally supported by the new major market competitor with a similar clinical mechanism of action in IL 13 at once monthly maintenance dosing, which is priced significantly higher. LEO Pharma’s Adbry syringe still continues to be the lowest net cost price product in the Atopic Dermatitis category. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None LEO Pharma A/S, the Danish parent company of LEO Pharma, entered into a license and royalty agreement with AstraZeneca on June 30, 2016 for the exclusive, global rights to tralokinumab in atopic dermatitis and any future dermatology indications.
Rx0000276 LEO Pharma Inc. 04/18/2025 50222034602 Adbry (tralokinumab-ldrm) solution injection, 150 mg/mL, 2 syringes in 1 carton > 1 mL in 1 syringe 01/01/2025 115.17 2034.69 01/09/2027 Single Source Drug None None None 1 LEO increased the price due to increasing competition and a growing utilization of our product in once monthly dosing. This is additionally supported by the new major market competitor with a similar clinical mechanism of action in IL 13 at once monthly maintenance dosing, which is priced significantly higher. LEO Pharma’s Adbry syringe still continues to be the lowest net cost price product in the Atopic Dermatitis category. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None LEO Pharma A/S, the Danish parent company of LEO Pharma, entered into a license and royalty agreement with AstraZeneca on June 30, 2016 for the exclusive, global rights to tralokinumab in atopic dermatitis and any future dermatology indications.
Rx0000025 Lundbeck LLC 04/29/2025 67386031401 Onfi 10mg. 100 Tablets 01/02/2025 149.08 3130.68 None Innovator Multiple Source Drug None None None 1 "Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." None None 1 None None None None None None None None None None None
Rx0000025 Lundbeck LLC 04/29/2025 67386031501 Onfi 20mg. 100 Tablets 01/02/2025 298.16 6261.30 None Innovator Multiple Source Drug None None None 1 "Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." None None 1 None None None None None None None None None None None
Rx0000025 Lundbeck LLC 04/29/2025 67386013051 Vyepti 100mg/ml single dose vial 01/02/2025 60.32 1888.15 None Single Source Drug None None None 1 "Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." None None 1 None None None None None None None None None None None